SCHEMBL9893820

SCHEMBL9893820

CNC(=O)c1nc(-c2ccccc2)n(-c2cccc(Cl)c2)c1-c1cc(Cl)ccc1OC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 4/20 0.54
TUBB4A P04350 2/20 0.42
TUBB P07437 2/20 0.42
TUBA3C P0DPH7 2/20 0.42
TUBA1B P68363 2/20 0.42
TUBA4A P68366 2/20 0.42
TUBB4B P68371 2/20 0.42
TUBB3 Q13509 2/20 0.42
TUBB2A Q13885 2/20 0.42
TUBB8 Q3ZCM7 2/20 0.42
TUBA3E Q6PEY2 2/20 0.42
TUBA1A Q71U36 2/20 0.42
TUBA1C Q9BQE3 2/20 0.42
TUBB6 Q9BUF5 2/20 0.42
TUBB2B Q9BVA1 2/20 0.42
TUBB1 Q9H4B7 2/20 0.42
PDE4D Q08499 1/20 0.41
CTSA P10619 3/20 0.41
MAPT P10636 3/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9893877 0.90 MDM2 (0.68) MDM2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL9893962 0.86 MDM2 (0.54) MDM2CTSAMAPTLMNATP53
SCHEMBL9893773 0.84 MDM2 (0.76) MDM2POLBLMNATP53HTT
SCHEMBL1438008 0.82 MDM2 (0.69) MDM2MAPTPOLBTP53HTT
SCHEMBL9894355 0.82 MDM2 (0.56) MDM2PDE4DPOLBGABRA2GABRB2
SCHEMBL9893421 0.80 MDM2 (0.65) MDM2POLBLMNAHTTMEN1
SCHEMBL1437306 0.80 MDM2 (0.65) MDM2PDE4DPOLBTP53MEN1
SCHEMBL9894220 0.78 MDM2 (0.70) MDM2CTSATP53ALDH1A1HPGD
SCHEMBL1437159 0.78 MDM2 (0.61) MDM2PDE4DPOLB
SCHEMBL1438284 0.77 MDM2 (0.60) MDM2PDE4DCTSAMAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS NOVARTIS AG (CH) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS MDM4, MDM2, TP53 MDM2 2/4885TUBB4A 1085/4885TUBB 2355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.